Uni-Bio Science Group Ltd
HKEX:690
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| HK |
|
Uni-Bio Science Group Ltd
HKEX:690
|
644.9m HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -239 513 300% |
| 30th Percentile | -12.9% |
| Median | 0.5% |
| 70th Percentile | 5.3% |
| Max | 203 056% |
Other Profitability Ratios
Uni-Bio Science Group Ltd
Glance View
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. The company employs 326 full-time employees The company went IPO on 2001-11-12. The firm operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Uni-Bio Science Group Ltd is 15.5%, which is in line with its 3-year median of 15.5%.
Over the last 3 years, Uni-Bio Science Group Ltd’s Net Margin has increased from -1.8% to 15.5%. During this period, it reached a low of -1.8% on May 30, 2022 and a high of 19.4% on Jun 30, 2024.
